Head-to-head · WeighScore
Boston Medical Group vs Tell Her Doc
The verdict
Boston Medical Group takes it — 61.9/100 to 57.4/100.
Boston Medical Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Boston Medical Group is an established medical group running a 12-week compounded GLP-1 weight-loss programme.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Boston Medical Group | Tell Her Doc |
|---|---|---|
| WeighScore | 61.9/100 | 57.4/100 |
| Grade | C | C |
| Scorecard rank | #279 | #400 |
| Semaglutide | $199/mo (starting strength, rising with dose, compounded) | $269/mo (microdose tier, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | 7 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #279 · C
Strengths
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
Where it loses points
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
- The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
- Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #400 · C
Strengths
- Full compounded GLP-1 lineup — semaglutide and tirzepatide in injection, oral and orally-dissolving-tablet forms, plus microdoses
- Names its compounding pharmacy partner (Casa Pharma RX), which is independently listed in our pharmacy registry
- No monthly membership, cancel anytime, free discreet shipping; HSA/FSA eligible with buy-now-pay-later plans
- Serves patients in all 50 states via a private online consultation
Where it loses points
- 'All sales are final' — no refunds once medication has left the pharmacy
- Exact price is plan-dependent, shown after you pick a product; advertised 'starting at $269', with a lower $140 intro on oral semaglutide
- References LegitScript but without an independently verifiable seal — we couldn't confirm certification
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.